Frontier Biotechnologies Third Quarter 2024 Earnings: CN¥0.089 loss per share (vs CN¥0.19 loss in 3Q 2023)
Frontier Biotechnologies (SHSE:688221) Third Quarter 2024 Results
Key Financial Results
- Revenue: CN¥40.6m (up 36% from 3Q 2023).
- Net loss: CN¥33.0m (loss narrowed by 52% from 3Q 2023).
- CN¥0.089 loss per share (improved from CN¥0.19 loss in 3Q 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Frontier Biotechnologies shares are up 22% from a week ago.
Risk Analysis
We should say that we've discovered 1 warning sign for Frontier Biotechnologies that you should be aware of before investing here.
New: AI Stock Screener & Alerts
Our new AI Stock Screener scans the market every day to uncover opportunities.
• Dividend Powerhouses (3%+ Yield)
• Undervalued Small Caps with Insider Buying
• High growth Tech and AI Companies
Or build your own from over 50 metrics.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About SHSE:688221
Frontier Biotechnologies
A commercial-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes various medicines that improve patient health.
Excellent balance sheet minimal.
